Q3 2024 Earnings Forecast for Knight Therapeutics Inc. Issued By Stifel Canada (TSE:GUD)

Knight Therapeutics Inc. (TSE:GUD) – Analysts at Stifel Canada dropped their Q3 2024 EPS estimates for Knight Therapeutics in a report issued on Monday, August 12th. Stifel Canada analyst J. Keywood now forecasts that the company will post earnings per share of $0.06 for the quarter, down from their prior estimate of $0.07. Stifel Canada currently has a “Strong-Buy” rating on the stock. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.03 per share.

Separately, Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and upped their price objective for the stock from C$5.75 to C$6.75 in a research note on Tuesday.

Knight Therapeutics Stock Up 0.4 %

Shares of TSE GUD opened at C$5.69 on Wednesday. Knight Therapeutics has a 12-month low of C$4.35 and a 12-month high of C$6.22. The stock’s fifty day simple moving average is C$5.66 and its two-hundred day simple moving average is C$5.64. The stock has a market capitalization of C$576.85 million, a PE ratio of -35.56, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.46. The company has a current ratio of 3.34, a quick ratio of 1.79 and a debt-to-equity ratio of 9.20.

Insider Activity at Knight Therapeutics

In other Knight Therapeutics news, Senior Officer Amal Khouri sold 5,000 shares of Knight Therapeutics stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of C$5.75, for a total value of C$28,750.00. In other Knight Therapeutics news, Senior Officer Amal Khouri sold 5,000 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of C$5.75, for a total value of C$28,750.00. Also, Director Robert Nathaniel Lande sold 20,000 shares of the business’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of C$5.94, for a total value of C$118,710.00. Insiders sold 80,000 shares of company stock valued at $466,283 over the last 90 days. Insiders own 46.36% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.